CASTLE ROCK, Colo.,
Feb. 12, 2015 /PRNewswire/
-- Venaxis®, Inc. (Nasdaq: APPY), an in
vitro diagnostic company focused on advancing commercialization
of its CE Marked APPY1® Test, a rapid blood test for aiding
in identifying children, adolescent, and young adult patients in
the emergency room who are at low risk for appendicitis, today
announced that the Company will host an investor conference call to
discuss business matters, including the recent FDA "Not
Substantially Equivalent" response, on February 13, 2015, at 8:30
a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
A live audio webcast will be accessible via the Investor
Relations section of the Venaxis website, www.venaxis.com/webcast/.
Participants and investors may also access the conference call by
dialing 1-888-455-2260 (U.S.) or 1-719-457-2645 (Toll -
International).
A replay of the call will be available approximately an hour
after the end of the conference call on the Company's website. To
access the webcast, please visit the investor relations section of
the Venaxis website at www.venaxis.com/webcast/.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on
the clinical development and commercialization of its CE Marked
APPY1 Test, the Company's rapid blood based test for
appendicitis. This unique appendicitis test has projected high
sensitivity and negative predictive value and is being developed to
aid in the identification of patients at low probability for acute
appendicitis, allowing for more conservative patient management.
The APPY1 Test is being developed initially for pediatric,
adolescent, and young adult patients with abdominal pain, as this
population is at the highest risk for appendicitis and has the
highest risk of long-term health effects associated with CT
imaging. While the FDA clearance process and status is being
evaluated, a limited commercial launch for the APPY1 Test is
advancing in select European countries. For more information, visit
www.venaxis.com.
Forward-Looking Statements
This press release
includes "forward-looking statements" of Venaxis, Inc. ("Venaxis")
as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in
this press release that address activities, events or developments
that Venaxis believes or anticipates will or may occur in the
future are forward-looking statements. These statements are based
on certain assumptions made based on experience, expected future
developments and other factors Venaxis believes are appropriate in
the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the
control of Venaxis. Investors are cautioned that any such
statements are not guarantees of future performance. Actual results
or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including
our ability to obtain FDA clearance or approval to distribute the
APPY1 Test in the U.S., maintain CE Marking, cost
effectively manufacture and generate revenues from the APPY1
Test at a profitable price point, execute agreements required to
successfully advance the company's objectives, retain the
management team to advance the products, overcome adverse changes
in market conditions and the regulatory environment, obtain and
enforce intellectual property rights, and realize value of
intangible assets. Furthermore, Venaxis does not intend (and is not
obligated) to update publicly any forward-looking statements. The
contents of this press release should be considered in conjunction
with the risk factors contained in Venaxis' recent filings with the
SEC, including its Form 10-K for the year ended December 31, 2013, filed with the SEC on
March 28, 2014.
Venaxis and APPY1 are registered trademarks and
APPYAnalytics is a trademark of Venaxis, Inc.
Contact – Jed Mahan,
jmahan@venaxis.com; (303) 794-2000 Ext. 255
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/venaxis-business-update-300035106.html
SOURCE Venaxis, Inc.